394 related articles for article (PubMed ID: 29338602)
21. Examining trends in the administration of "as needed" medications to inpatients with behavioral and psychological symptoms of dementia.
Neumann RD; Faris P; Klassen R
Am J Alzheimers Dis Other Demen; 2015 May; 30(3):247-56. PubMed ID: 25969566
[TBL] [Abstract][Full Text] [Related]
22. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia.
Ujkaj M; Davidoff DA; Seiner SJ; Ellison JM; Harper DG; Forester BP
Am J Geriatr Psychiatry; 2012 Jan; 20(1):61-72. PubMed ID: 22143072
[TBL] [Abstract][Full Text] [Related]
25. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
Ostinelli EG; Hussein M; Ahmed U; Rehman FU; Miramontes K; Adams CE
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD009412. PubMed ID: 29634083
[TBL] [Abstract][Full Text] [Related]
26. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
Banerjee S; Farina N; Henderson C; High J; Stirling S; Shepstone L; Fountain J; Ballard C; Bentham P; Burns A; Fox C; Francis P; Howard R; Knapp M; Leroi I; Livingston G; Nilforooshan R; Nurock S; O'Brien J; Price A; Thomas AJ; Swart AM; Telling T; Tabet N
Health Technol Assess; 2023 Oct; 27(23):1-108. PubMed ID: 37929672
[TBL] [Abstract][Full Text] [Related]
27. Advancements in the treatment of agitation in Alzheimer's disease.
Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
[TBL] [Abstract][Full Text] [Related]
28. Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care.
Gallagher D; Herrmann N
Neurodegener Dis Manag; 2015; 5(1):75-83. PubMed ID: 25711456
[TBL] [Abstract][Full Text] [Related]
29. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
[TBL] [Abstract][Full Text] [Related]
30. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Rabinowitz J; Katz IR; De Deyn PP; Brodaty H; Greenspan A; Davidson M
J Clin Psychiatry; 2004 Oct; 65(10):1329-34. PubMed ID: 15491235
[TBL] [Abstract][Full Text] [Related]
31. Management of agitation and aggression associated with Alzheimer disease.
Ballard CG; Gauthier S; Cummings JL; Brodaty H; Grossberg GT; Robert P; Lyketsos CG
Nat Rev Neurol; 2009 May; 5(5):245-55. PubMed ID: 19488082
[TBL] [Abstract][Full Text] [Related]
32. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.
Wang LY; Shofer JB; Rohde K; Hart KL; Hoff DJ; McFall YH; Raskind MA; Peskind ER
Am J Geriatr Psychiatry; 2009 Sep; 17(9):744-51. PubMed ID: 19700947
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological treatment of behavioural and psychological symptoms of dementia in psychogeriatric inpatient units.
Restifo S; Lemon V; Waters F
Australas Psychiatry; 2011 Feb; 19(1):59-63. PubMed ID: 21189108
[TBL] [Abstract][Full Text] [Related]
34. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A
J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749
[TBL] [Abstract][Full Text] [Related]
35. Management of neuropsychiatric symptoms in people with dementia.
Ballard C; Corbett A
CNS Drugs; 2010 Sep; 24(9):729-39. PubMed ID: 20806986
[TBL] [Abstract][Full Text] [Related]
36. New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis.
Stahl SM
CNS Spectr; 2018 Oct; 23(5):291-297. PubMed ID: 30382934
[TBL] [Abstract][Full Text] [Related]
37. Antidepressants for agitation and psychosis in dementia.
Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
[TBL] [Abstract][Full Text] [Related]
38. Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?
Gallagher D; Herrmann N
Drugs; 2014 Oct; 74(15):1747-55. PubMed ID: 25239267
[TBL] [Abstract][Full Text] [Related]
39. An update on the advancements in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Antonsdottir IM
Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
[TBL] [Abstract][Full Text] [Related]
40. Haloperidol for agitation in dementia.
Lonergan E; Luxenberg J; Colford J
Cochrane Database Syst Rev; 2001; (4):CD002852. PubMed ID: 11687166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
